Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,472Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M23.2EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book4.910-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %0.2PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M39,150,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with XBI

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
XBIFirst Eagle Investment 2016-09-30 Sold Out $55.11 - $68.83
($61.74)
$ 63.152%Sold Out0
XBIFirst Eagle Investment 2016-03-31 Buy $45.73 - $70.2
($52.16)
$ 63.1521%New holding18,150
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

XBI is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


XBI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.48566.14view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94272.79view
DINWOODIE, TYLER WAYNE PAULSenior Officer 2017-01-16Buy4,000$0.1737047.06view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.364543.38view
Bebek, IvanDirector 2017-01-16Buy8,990$3.381768.34view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.4115302.44view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91126.26view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.27907.18view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.384.59view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.1542000view

Quarterly/Annual Reports about XBI:

    News about XBI:

    Articles On GuruFocus.com
    Cisco: A 10% Dividend Increase Could Be On the Way Jan 22 2017 
    If You Think Intel Is Dead Money, Think Again Jan 22 2017 
    AbbVie Gets FDA Approval for Lymphoma Drug Jan 22 2017 
    Activision Blizzard Is Poised to Move Higher Jan 22 2017 
    3 Great Stocks for Your 2017 Core Investment Portfolio Jan 22 2017 
    BioCorRx Receives New Funding for Opioid Drug Jan 22 2017 
    3M Could Increase Dividend by Up to 10% Jan 22 2017 
    2018 Will Be IBM CEO Ginni Rometty’s Year of Vindication Jan 22 2017 
    Why Barrick Gold Is a Long Term Pick Jan 21 2017 
    Will Samsung Be Able to Repair Its Brand Image? Jan 21 2017 

    More From Other Websites
    4 Top Biotech Mutual Funds for 2017 Jan 18 2017
    Biotech ETFs: When Will The Pain End? Jan 17 2017
    Biotech ETFs Continue To Bleed Jan 12 2017
    Trump's First Press Conference Puts These ETFs in Focus Jan 12 2017
    Trump's Remarks Show Why Pharma Sector Is 'Barely Investable': More Squawk From Jim Cramer Jan 12 2017
    5 Things You Must Know Before the Market Opens Thursday Jan 12 2017
    Donald Trump Whacks European Stocks Jan 12 2017
    European Pharma Shares Hammered After Trump Press Conference Attack Jan 12 2017
    Dow moves within 50 points of 20,000 after Trump news conference Jan 11 2017
    Nasdaq Posts Another Record Close in Unpredictable Trump-Triggered Trading Session Jan 11 2017
    P.M. Funds Roundup: Mexico, Biotech ETFs Get Trumped; Is It RIP For Bitcoin ETF? Jan 11 2017
    Stocks Back to Gains in Unsettled Trade After Trump News Conference Jan 11 2017
    Good Enough? Trump Outlines Plans to Separate From Business but Will Not Divest Holdings Jan 11 2017
    Trump Takes Aim at Pharma but Investors Shouldn't Panic Jan 11 2017
    Stocks Recover But Pharma Still Down After Trump's Threats Jan 11 2017
    Biotech, Pharma ETFs Sink; Trump Promises "Bidding Procedures" Jan 11 2017
    Biotech ETFs fall as Trump says more bidding needed on drugs Jan 11 2017
    How Was Incyte’s Profitability in 3Q16? Jan 09 2017
    The 'Super Bowl' for health care investors Jan 06 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)